Definition A trial that asked whether tolvaptan, a vasopressin V2 receptor blocker, improved outcomes of patients hospitalised with heart failure.
Logistics Multicentre, multinational event-driven, randomised, double-blind, placebo-controlled study involving 4133 patients.
Conclusion No it doesn’t.
Abbreviation for Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan
Reference J Am Coll Cardio 2008; 52:1640